Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

therapy of dermatological diseases," said Robert Booth .

Background

About Cathepsin S and VBY-036

Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes proteolytic cleavage of membrane-bound fractalkine from the surface of neurons to release soluble fractalkine.  Fractalkine is a potent chemokine that stimulates the recruitment of inflammatory cells to the sites of neuronal damage and activates microglia.  Microglia are macrophage-like cells that are implicated as key drivers in the pathogenesis of chronic neuropathic pain syndromes.  In model systems, cathepsin S mediated microglial activation is essential in the development of pain.  The inhibition of cathepsin S results in a reduction in pain, as well as prevention of pain in preclinical models of chemotherapy-induced neuropathic pain and diabetic neuropathy.

VBY-036 is an optimized cathepsin S inhibitor that is a potent, competitive and reversible inhibitor of cathepsin S.  It has picomolar inhibitory potency against the isolated cathepsin S enzyme and nanomolar activity in cellular assays.  VBY-036 is also highly selective against related human cathepsins as well as other enzymes, and sustained cathepsin S inhibition after oral dosing has been demonstrated in vivo through the use of a biomarker.  The compound has been tested in pre-clinical studies and is now entering the next phase - a phase 1 clinical trial in healthy human volunteers.  The VBY-036 program is a novel approach to the treatment of pain and may result in a safe and effective oral therapeutic for an important unmet medical need.  

About Virobay, Inc.

Founded in 2006, Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a class of enzymes that are key mediators in a variety of diseases, including autoimmunity, neuropath
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a company overview at the Nomura Biotechnology Conference on Thursday, ... Boston, MA. A live webcast of ... section of the Company,s website, www.isispharm.com .  A replay ... and will be archived for a limited time. ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information ... recent Ebola concern in the United States ... virus.  The healthcare market researcher said the FDA,s Emergency Use ... vitro diagnostic tests for the detection of the Ebola ... proved useful.  Kalorama routinely assess the IVD industry and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... October 6, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... tiaras to anklets are treasures but these gemstones inside ... Reserve University researchers are building implants made of diamond ... and electrical changes in the brain of patients suffering ... movement in the paralyzed. The work of Heidi ...
... Oct. 4 issue of the high-impact journal, Applied ... the University of Cincinnati and start-up company Gamma Dynamics ... electronic devices. This patent-pending electrofluidics breakthrough by the ... partner companies Gamma Dynamics, Dupont and Sun Chemical follows ...
Cached Biology Technology:Elsevier Introduces Article-Based Publishing to Increase Publication Speed 2Elsevier Introduces Article-Based Publishing to Increase Publication Speed 3Elsevier Introduces Article-Based Publishing to Increase Publication Speed 4Elsevier Introduces Article-Based Publishing to Increase Publication Speed 5Elsevier Introduces Article-Based Publishing to Increase Publication Speed 6Elsevier Introduces Article-Based Publishing to Increase Publication Speed 7Elsevier Introduces Article-Based Publishing to Increase Publication Speed 8Gem of an idea: A flexible diamond-studded electrode implanted for life 2Gem of an idea: A flexible diamond-studded electrode implanted for life 3Breakthrough e-display means electronics with high speed, high readability and low power usage 2Breakthrough e-display means electronics with high speed, high readability and low power usage 3Breakthrough e-display means electronics with high speed, high readability and low power usage 4
(Date:10/31/2014)... steps involved in programmed cell death, offering new targets ... neurodegenerative diseases. , The research teams from the ... the three-dimensional structure of a key cell death protein ... it causes cell death. Their studies were published in ... Proceedings of the National Academy of Sciences . ...
(Date:10/31/2014)... 2014  HITLAB SM , a healthcare innovation ... inaugural HITLAB Innovators Summit SM on December ... will partner with the Clinton Foundation,s Health Matters ... Columbia Business School Alumni Club of ... and Operations Research, bringing together leaders in healthcare ...
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
Breaking Biology News(10 mins):A matter of life and death: Cell death proteins key to fighting disease 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Identifying the source of stem cells 2
... from brake linings and mining operations can affect salmon ... a Washington State University researcher. Jenifer McIntyre found the ... they won,t detect a compound that ordinarily alerts them ... is not getting the information it needs to make ...
... Switzerland. Research to be presented at the Annual Meeting of ... foremost society for research into all aspects of eating and ... reduces the quality of sleep in rats. Using radio-telemetry, ... consumed a high fat diet for 8 weeks. Compared to ...
... debilitating illnesses one can develop. Currently, the disease afflicts 6.5 ... to between 11 and 16 million, or 1 in 85 ... one to grow forgetful, confused and, eventually, catatonic. Recently approved ... consensus on the underlying mechanism of the disease. "We ...
Cached Biology News:Copper making salmon prone to predators 2Small molecule may play big role in Alzheimer's disease 2Small molecule may play big role in Alzheimer's disease 3Small molecule may play big role in Alzheimer's disease 4
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: